Praxis Precision Medicines (PRAX) to Announce Earnings on Thursday

Praxis Precision Medicines (NASDAQ:PRAX) is expected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Praxis Precision Medicines to post earnings of ($3.67) per share and revenue of $1.25 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Praxis Precision Medicines (NASDAQ:PRAX) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($3.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.58) by $0.38. On average, analysts expect Praxis Precision Medicines to post $-15 EPS for the current fiscal year and $-12 EPS for the next fiscal year.

Praxis Precision Medicines Trading Up 1.5%

PRAX stock opened at $310.07 on Wednesday. The business’s 50-day moving average price is $304.18 and its two-hundred day moving average price is $314.95. The firm has a market cap of $8.64 billion, a PE ratio of -23.19 and a beta of 2.78. Praxis Precision Medicines has a 1-year low of $37.19 and a 1-year high of $366.52.

Analysts Set New Price Targets

PRAX has been the topic of several recent analyst reports. Oppenheimer reiterated an “outperform” rating and set a $650.00 price objective (down from $750.00) on shares of Praxis Precision Medicines in a report on Tuesday, June 2nd. BTIG Research restated a “buy” rating and set a $810.00 target price on shares of Praxis Precision Medicines in a report on Wednesday, July 29th. The Goldman Sachs Group assumed coverage on shares of Praxis Precision Medicines in a research report on Monday, July 13th. They set a “buy” rating and a $447.00 price objective for the company. Wedbush cut their price objective on shares of Praxis Precision Medicines from $166.00 to $162.00 and set an “underperform” rating on the stock in a research report on Tuesday, June 2nd. Finally, Truist Financial set a $616.00 price target on Praxis Precision Medicines and gave the company a “buy” rating in a report on Tuesday, June 2nd. Four investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $563.50.

Insider Buying and Selling at Praxis Precision Medicines

In related news, Director Jill Desimone sold 11,600 shares of Praxis Precision Medicines stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $311.32, for a total value of $3,611,312.00. Following the sale, the director owned 2,337 shares of the company’s stock, valued at approximately $727,554.84. The trade was a 83.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Praxis Precision Medicines

Institutional investors and hedge funds have recently made changes to their positions in the stock. Orbis Allan Gray Ltd acquired a new position in Praxis Precision Medicines during the fourth quarter worth approximately $369,946,000. RA Capital Management L.P. bought a new stake in shares of Praxis Precision Medicines during the 4th quarter worth about $110,170,000. Woodline Partners LP grew its stake in Praxis Precision Medicines by 808.9% in the 3rd quarter. Woodline Partners LP now owns 417,669 shares of the company’s stock valued at $22,136,000 after buying an additional 371,717 shares during the last quarter. T. Rowe Price Investment Management Inc. acquired a new position in Praxis Precision Medicines in the 4th quarter valued at about $81,464,000. Finally, Logos Global Management LP raised its holdings in Praxis Precision Medicines by 200.0% in the 4th quarter. Logos Global Management LP now owns 375,000 shares of the company’s stock valued at $110,528,000 after acquiring an additional 250,000 shares during the period. Institutional investors own 67.84% of the company’s stock.

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.